Center Laboratories (4123) - Net Assets
Based on the latest financial reports, Center Laboratories (4123) has net assets worth NT$19.64 Billion TWD (≈ $618.69 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$25.81 Billion ≈ $813.14 Million USD) and total liabilities (NT$6.17 Billion ≈ $194.45 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 4123 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$19.64 Billion |
| % of Total Assets | 76.09% |
| Annual Growth Rate | 26.22% |
| 5-Year Change | -12.5% |
| 10-Year Change | 21.3% |
| Growth Volatility | 64.95 |
Center Laboratories - Net Assets Trend (2006–2024)
This chart illustrates how Center Laboratories's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Center Laboratories for the complete picture of this company's asset base.
Annual Net Assets for Center Laboratories (2006–2024)
The table below shows the annual net assets of Center Laboratories from 2006 to 2024. For live valuation and market cap data, see Center Laboratories stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$18.05 Billion ≈ $568.82 Million |
-10.69% |
| 2023-12-31 | NT$20.22 Billion ≈ $636.92 Million |
+5.01% |
| 2022-12-31 | NT$19.25 Billion ≈ $606.55 Million |
-8.73% |
| 2021-12-31 | NT$21.09 Billion ≈ $664.61 Million |
+2.23% |
| 2020-12-31 | NT$20.63 Billion ≈ $650.10 Million |
+33.48% |
| 2019-12-31 | NT$15.46 Billion ≈ $487.02 Million |
-0.06% |
| 2018-12-31 | NT$15.47 Billion ≈ $487.30 Million |
-8.31% |
| 2017-12-31 | NT$16.87 Billion ≈ $531.48 Million |
+6.61% |
| 2016-12-31 | NT$15.82 Billion ≈ $498.51 Million |
+6.31% |
| 2015-12-31 | NT$14.88 Billion ≈ $468.92 Million |
+114.58% |
| 2014-12-31 | NT$6.94 Billion ≈ $218.54 Million |
+38.38% |
| 2013-12-31 | NT$5.01 Billion ≈ $157.93 Million |
+44.47% |
| 2012-12-31 | NT$3.47 Billion ≈ $109.32 Million |
+56.73% |
| 2011-12-31 | NT$2.21 Billion ≈ $69.75 Million |
+1.43% |
| 2010-12-31 | NT$2.18 Billion ≈ $68.76 Million |
+3.29% |
| 2009-12-31 | NT$2.11 Billion ≈ $66.57 Million |
+268.69% |
| 2008-12-31 | NT$573.09 Million ≈ $18.06 Million |
+21.63% |
| 2007-12-31 | NT$471.17 Million ≈ $14.84 Million |
+72.54% |
| 2006-12-31 | NT$273.07 Million ≈ $8.60 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Center Laboratories's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4199.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$19.42 Billion | 107.58% |
| Total Equity | NT$18.05 Billion | 100.00% |
Center Laboratories Competitors by Market Cap
The table below lists competitors of Center Laboratories ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hangzhou Haoyue Personal Care Co Ltd
SHG:605009
|
$906.99 Million |
|
Guangdong Fuxin Technology Co. Ltd. A
SHG:688662
|
$907.09 Million |
|
Beijing Philisense Tech
SHE:300287
|
$907.31 Million |
|
Koza Anadolu Metal Madencilik Isletmeleri AS
IS:KOZAA
|
$907.44 Million |
|
SolGold Plc
F:S8F
|
$906.54 Million |
|
Metalurgica Gerdau S.A
SA:GOAU3
|
$906.45 Million |
|
Sipef NV
BR:SIP
|
$906.31 Million |
|
Aeva Technologies, Inc. Common Stock
NYSE:AEVA
|
$906.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Center Laboratories's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,756,854,000 to 18,054,477,000, a change of -1,702,377,000 (-8.6%).
- Net loss of 1,103,683,000 reduced equity.
- Dividend payments of 1,030,646,000 reduced retained earnings.
- New share issuances of 42,185,000 increased equity.
- Other comprehensive income decreased equity by 7,654,475,000.
- Other factors increased equity by 8,044,242,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-1.10 Billion | -6.11% |
| Dividends Paid | NT$1.03 Billion | -5.71% |
| Share Issuances | NT$42.19 Million | +0.23% |
| Other Comprehensive Income | NT$-7.65 Billion | -42.4% |
| Other Changes | NT$8.04 Billion | +44.56% |
| Total Change | NT$- | -8.62% |
Book Value vs Market Value Analysis
This analysis compares Center Laboratories's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.56x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 22.06x to 1.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | NT$1.77 | NT$39.00 | x |
| 2007-12-31 | NT$3.89 | NT$39.00 | x |
| 2008-12-31 | NT$3.43 | NT$39.00 | x |
| 2009-12-31 | NT$7.99 | NT$39.00 | x |
| 2010-12-31 | NT$7.20 | NT$39.00 | x |
| 2011-12-31 | NT$5.46 | NT$39.00 | x |
| 2012-12-31 | NT$7.16 | NT$39.00 | x |
| 2013-12-31 | NT$10.50 | NT$39.00 | x |
| 2014-12-31 | NT$13.29 | NT$39.00 | x |
| 2015-12-31 | NT$13.46 | NT$39.00 | x |
| 2016-12-31 | NT$13.67 | NT$39.00 | x |
| 2017-12-31 | NT$17.91 | NT$39.00 | x |
| 2018-12-31 | NT$22.86 | NT$39.00 | x |
| 2019-12-31 | NT$22.65 | NT$39.00 | x |
| 2020-12-31 | NT$28.04 | NT$39.00 | x |
| 2021-12-31 | NT$28.41 | NT$39.00 | x |
| 2022-12-31 | NT$29.86 | NT$39.00 | x |
| 2023-12-31 | NT$29.76 | NT$39.00 | x |
| 2024-12-31 | NT$25.06 | NT$39.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Center Laboratories utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -68.22%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.41x
- Recent ROE (-6.11%) is below the historical average (7.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 5.62% | 6.05% | 0.51x | 1.81x | NT$-11.96 Million |
| 2007 | 24.33% | 38.25% | 0.46x | 1.38x | NT$67.54 Million |
| 2008 | 8.58% | 12.47% | 0.36x | 1.92x | NT$-7.55 Million |
| 2009 | 8.77% | 29.94% | 0.19x | 1.53x | NT$-19.43 Million |
| 2010 | 0.78% | 2.28% | 0.23x | 1.47x | NT$-153.43 Million |
| 2011 | 2.57% | 6.22% | 0.26x | 1.58x | NT$-122.73 Million |
| 2012 | 4.25% | 13.99% | 0.18x | 1.73x | NT$-135.22 Million |
| 2013 | 1.41% | 7.00% | 0.14x | 1.48x | NT$-317.27 Million |
| 2014 | 6.33% | 37.08% | 0.09x | 1.83x | NT$-193.13 Million |
| 2015 | 6.40% | 6.21% | 0.24x | 4.24x | NT$-237.10 Million |
| 2016 | 0.29% | 0.13% | 0.50x | 4.47x | NT$-659.74 Million |
| 2017 | 3.68% | 1.29% | 0.51x | 5.63x | NT$-429.69 Million |
| 2018 | 46.54% | 28.10% | 1.06x | 1.56x | NT$4.78 Billion |
| 2019 | -1.53% | -14.16% | 0.06x | 1.72x | NT$-1.53 Billion |
| 2020 | 21.06% | 528.07% | 0.03x | 1.55x | NT$1.99 Billion |
| 2021 | 9.59% | 363.16% | 0.02x | 1.61x | NT$-77.75 Million |
| 2022 | -2.99% | -74.98% | 0.03x | 1.31x | NT$-2.50 Billion |
| 2023 | -5.30% | -75.15% | 0.05x | 1.37x | NT$-3.02 Billion |
| 2024 | -6.11% | -68.22% | 0.06x | 1.41x | NT$-2.91 Billion |
Industry Comparison
This section compares Center Laboratories's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,692,263,800
- Average return on equity (ROE) among peers: 5.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Center Laboratories (4123) | NT$19.64 Billion | 5.62% | 0.31x | $906.73 Million |
| Grape King Bio Ltd (1707) | $1.77 Billion | 10.20% | 0.42x | $525.05 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.98 Billion | 9.81% | 0.25x | $343.42 Million |
| Maywufa Co Ltd (1731) | $1.65 Billion | 2.55% | 0.49x | $90.66 Million |
| ScinoPharm Taiwan Ltd (1789) | $10.54 Billion | 4.20% | 0.19x | $505.73 Million |
| Lotus Pharmaceutical Co Ltd (1795) | $7.70 Billion | 0.10% | 1.03x | $1.83 Billion |
| GeneFerm Biotechnology Co Ltd (1796) | $788.18 Million | -2.86% | 0.45x | $49.64 Million |
| LIWANLI Innovation Co Ltd (3054) | $661.02 Million | 0.00% | 0.12x | $167.70 Million |
| YungShin Global Holding Corp (3705) | $5.06 Billion | 9.31% | 0.15x | $466.59 Million |
| TTY Biopharm Co Ltd (4105) | $7.51 Billion | 19.30% | 0.45x | $581.27 Million |
| Phytohealth Corp (4108) | $2.27 Billion | -2.08% | 0.04x | $76.66 Million |
About Center Laboratories
Center Laboratories, Inc., a pharmaceutical company, develops, manufactures, and sells pharmaceuticals in Taiwan and internationally. The company offers general medication pharmaceuticals comprising antipyretics and analgesics, bronchodilators, anti-inflammatory preparations, antihistamines, expectorants, narcotic antitussives and expectorants, gastrointestinal preparations, non-narcotic antituss… Read more